du.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Survival rate among patients receiving oral cryotherapy in connection with myeloablative therapy followed by bone marrow transplantation
Dalarna University, School of Education, Health and Social Studies, Health and Caring Sciences/Oral Health Science.ORCID iD: 0000-0002-7972-1470
2009 (English)In: MASCC/ISOO International Symposium, Rom, 2009Conference paper, Published paper (Refereed)
Abstract [en]

Objectives: Oral cryotherapy has been proven to alleviate symptoms of mucositis, a major complication in myeloablative therapy. In a randomised controlled trial it was shown that patients receiving oral cryotherapy had less mucositis and fewer days with and lower dose of i.v. opioides than a control group receiving routine oral care. It is thus of interest to investigate if oral cryotherapy may be harmful to patients. Objectiv: The objective with the present study was to evaluate if there was a difference in survival rate for patients receiving oral cryotherapy in connection with myeloablative therapy followed by BMT compare to patients receiving routine oral care. Methods: Seventy eight patients (mean age 52.0 (12.9) years, range 19 – 69 years) treated with myeloablative therapy followed by BMT were randomised to oral cryotherapy (n=39) or routine oral care (n=39). Survival data was based on a review of the patient’s medical records after four years. Results: During follow-up, 25 of the patients receiving oral cryotherapy survived while 16 of the patients receiving routine oral care survived (odds ratio 0.39, 95 % CI 0.15-0.97, p<0.05). Conclusions: Oral cryotherapy provides no evidence of harm in patients receiving myeloablative therapy followed by BMT. Further analyses are needed to explore the difference in survival rate.

Place, publisher, year, edition, pages
Rom, 2009.
National Category
Clinical Medicine
Research subject
Hälsa och välfärd, Oral cryoterapi för patienter som behandlas med cytostatika
Identifiers
URN: urn:nbn:se:du-4176OAI: oai:dalea.du.se:4176DiVA, id: diva2:522002
Conference
MASCC/ISOO International Symposium , Rom, June 26-28, 2009
Available from: 2009-08-31 Created: 2009-08-31 Last updated: 2016-01-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records BETA

Svanberg, AnncarinÖhrn, Kerstin

Search in DiVA

By author/editor
Svanberg, AnncarinÖhrn, Kerstin
By organisation
Health and Caring Sciences/Oral Health Science
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 567 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf